Radioprotection from radiation-induced lymphedema without tumor protection.

Area of Science:

• Oncology
• Radiotherapy
• Pharmacology

Background:

• Lymphedema, a common complication of cancer treatment involving lymph node dissection and radiation therapy, significantly impacts patient quality of life.
• Current preventive measures for lymphedema are often ineffective or unproven, highlighting the need for novel therapeutic strategies.
• Amifostine, an organic thiophosphate radioprotectant, is being investigated for its potential to mitigate radiation-induced tissue damage.

Purpose of the Study:

• To evaluate the efficacy of amifostine in preventing or delaying lymphedema development in a rodent model following radiation therapy.
• To determine if amifostine provides radioprotection to cancer cells, thereby not interfering with the therapeutic effects of radiation therapy.
• To assess amifostine's impact on wound healing and tissue lymphostasis in the context of radiation-induced lymphedema.

Main Methods:

• A rodent model was utilized, involving unilateral radical groin dissection followed by amifostine or placebo pre-treatment before single-dose post-operative groin radiation therapy.
• Hindlimb volumes, wound healing scores, and tissue lymphostasis were monitored to assess lymphedema development and severity.
• In vitro clonogenic assays and an in vivo MCF7 tumor xenograft model were employed to evaluate amifostine's effect on human breast cancer cell radiation sensitivity.

Main Results:

• Amifostine treatment markedly reduced limb lymphedema volume in the rodent model.
• Significant improvements in wound healing and tissue lymphostasis were observed in amifostine-treated animals.
• Both in vitro and in vivo studies confirmed that amifostine did not protect MCF7 breast cancer cells from the effects of radiation therapy.

Conclusions:

• Amifostine demonstrates significant potential in preventing and mitigating radiation-induced lymphedema and improving wound healing.
• The drug does not compromise the efficacy of radiation therapy against cancer cells, making it a potentially safe adjuvant treatment.
• These preclinical findings support further investigation into amifostine for clinical trials aimed at reducing lymphedema in at-risk cancer patients undergoing radiation therapy.